Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma

Fig. 3

Kaplan-Meier curves of DOR, PFS, and OS at stage 2 (ITT population). DOR as per IRC (a) and investigator assessments (b). PFS as per IRC (c) and investigator assessments (d). OS (e). DOR duration of response, mo months, OS overall survival, NR not reached, NE not estimable, CI confidence interval, IRC independent review committee, PFS progression-free survival

Back to article page